Treatment of recurrent or metastatic gastrointestinal stromal tumor: surgery or not.
- Author:
Ying-qiang SHI
1
Author Information
1. Department of Stomach and Soft Tissue Sarcoma Surgery, Shanghai Cancer Center, Fudan University, Shanghai 200032, China. yingqiangshi@126.com
- Publication Type:Journal Article
- MeSH:
Benzamides;
administration & dosage;
therapeutic use;
Combined Modality Therapy;
Gastrointestinal Stromal Tumors;
drug therapy;
surgery;
Humans;
Imatinib Mesylate;
Piperazines;
administration & dosage;
therapeutic use;
Pyrimidines;
administration & dosage;
therapeutic use
- From:
Chinese Journal of Gastrointestinal Surgery
2012;15(3):225-227
- CountryChina
- Language:Chinese
-
Abstract:
Currently, the treatment of recurrent or metastatic gastrointestinal stromal tumor(GIST) has become a tremendous challenge. Some international clinical trials revealed that imatinib might significantly improve the survival of patients with recurrent or metastatic GIST. Though the combination of surgery and imatinib has become an ideal treatment of metastatic GIST, there still exist some controversies regarding how to combine the two methods. Imatinib may influence the blood coagulation mechanism, therefore it is suggested that imatinib cessation should be performed a week before operation. Cytoreductive surgery has some clinical effects on recurrent or metastatic GIST, which can be combined with targeted therapy. Furthermore, the clinical trial for recurrent or metastatic GIST needs further evaluation.
